Publications by authors named "R Meley"

External quality assessment (EQA) is used to evaluate laboratory performance in tests of hemostasis; however, some esoteric tests are performed by too few centers in any one EQA program to allow valid statistical assessment. To explore the feasibility of pooling data from several EQA providers, an exercise was carried out by the External Quality Assurance in Thrombosis and Haemostasis group, using the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee (SSC) plasma standard for thrombophilia screening assays. Six EQA providers took part in this exercise, distributing the SSC plasma standard as a "blinded" sample to participants for thrombophilia tests between November 2020 and December 2021.

View Article and Find Full Text PDF

: Laboratory quality programs rely on internal quality control and external quality assessment (EQA). EQA programs provide unknown specimens for the laboratory to test. The laboratory's result is compared with other (peer) laboratories performing the same test.

View Article and Find Full Text PDF
Article Synopsis
  • FXIII deficiency is a rare bleeding disorder that requires early diagnosis and treatment; a quantitative FXIII activity test is recommended as the first screening method.
  • A multicenter study evaluated a new latex immunoassay, the K-Assay FXIII reagent, against the Berichrom FXIII chromogenic test and found a strong correlation and good inter-center accuracy.
  • The K-Assay is a reliable option for measuring FXIII antigen levels, especially when an activity assay is unavailable, aiding in the detection of FXIII deficiency.
View Article and Find Full Text PDF
Article Synopsis
  • Severe hemophilia A is an X-linked bleeding disorder that requires immune tolerance induction (ITI) as the best treatment option when inhibitors develop.
  • Patients treated with a high-purity human factor VIII/VWF concentrate (Octanate) showed promising results after unsuccessful attempts with recombinant FVIII and plasma-derived factor VIII.
  • The study highlights the potential benefits of laboratory assays like thrombin-generation tests (TGT) and epitope mapping in managing ITI, demonstrating a decrease in inhibitor levels with Octanate therapy.
View Article and Find Full Text PDF

Background: International organizations require from medical laboratories a quantitative statement of the uncertainty in measurement (UM) to help interpret patient results. The French accreditation body (COFRAC) recommends an approach (SH GTA 14 IQC/EQA method) using both internal quality control (IQC) and external quality assessment (EQA) data. The aim of this work was to validate an alternative way to quantify UM using only EQA results without any need for IQC data.

View Article and Find Full Text PDF